PRINCETON, N.J., Jan. 2, 2019 /PRNewswire/ -- Slayback Pharma LLC announced today that the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application ("ANDA") ...

Women receiving 17 α-hydroxyprogesterone caproate for the prevention of preterm labor might be at increased risk of developing gestational diabetes mellitus and should be screened accordingly This was ...

The Society for Maternal-Fetal Medicine (SMFM) praises the FDA's announcement on Makena. FDA has allowed certain pharmaceutical companies to compound hydroxyprogesterone caproate also known as 17p.

February 15, 2007 (San Francisco) — High-dose 17-alpha hydroxyprogesterone in women at risk for preterm labor effectively prevents preterm delivery by inhibiting cervical ripening and by blocking ...

A drug given to high-risk pregnant women to prevent premature birth may increase the risk of cancer in the women's children, a new study suggests. The drug hydroxyprogesterone caproate, a synthetic ...

The adult children of mothers who were treated with a drug that prevents miscarriage may have an increased risk of early-onset cancer, according to a new study. Children of women who received ...

To the Editor: After reading the article by Meis et al. (June 12 issue), 1 we strongly discourage practitioners from using 17 alpha-hydroxyprogesterone caproate in the care of women who have had ...

pregnant pregnancy Hydroxyprogesterone Caproate is used to lower the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. American ...

HealthDay News — For women with a prior preterm birth, cerclage plus 17α-hydroxyprogesterone caproate is associated with a significant reduction in delivery at less than 24 weeks of gestation compared ...

A drug commonly prescribed to pregnant women with a history of delivering babies early provides no benefit. In fact, this drug may even increase the risk of developing gestational diabetes. A drug ...